Clinical staging in the pathophysiology of psychotic and affective disorders: Facilitation of prognosis and treatment

Neurotoxicity Research

Volumn 18, Issue 3-4, 2010, Pages 211-228

  Archer, Trevor ^a   Kostrzewa, Richard M ^b   Palomo, Tomas ^c   Beninger, Richard J ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b East Tennessee State University   (United States)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Aging; Apathy; Comorbidity; Diagnosis; Prognosis; Progression; Schizophrenia affective disorders; Staging; Treatment

Indexed keywords

ARIPIPRAZOLE; CANNABIS; HALOPERIDOL; OLANZAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ALZHEIMER DISEASE; APATHY; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FAMILY THERAPY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; INTERMETHOD COMPARISON; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANIMALS; DISEASE PROGRESSION; HUMANS; MOOD DISORDERS; PROGNOSIS; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

CANNABIS;

EID: 78049277617     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-010-9161-7     Document Type: Review

References (290)

1. J Addington D Addington 2007 Patterns, predictors, and impact of substance use in early psychosis: a longitudinal study Acta Psychiatr Scand 115 304 309 17355521
2. J Addington KS Cadenhead TD Cannon B Cornblatt TH McGlashan DO Perkins LJ Seidman M Tsuang EF Walker SW Woods R Heinssen North American Prodrome Longitudinal Study 2007 North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research Schizophr Bull 33 665 672 17255119
3. GS Alexopoulos BS Meyers RC Young B Kalayam T Kakuma M Gabrielle JA Sirey J Hull 2000 Executive dysfunction and long-term outcomes of geriatric depression Arch Gen Psychiatr 57 285 290 10711915
4. Allen P, Seal ML, Valli I, Fusar-Poli P, Perlini C, Day F, Wood SJ, Williams SC, McGuire PK (2009) Altered prefrontal and hippocampal function during verbal encoding and recognition in people with prodromal symptoms of psychosis. Schizophr Bull. PMID:19933712
5. S Almond M Knapp C Francois M Toumi T Brugha 2004 Relapse in schizophrenia: costs, clinical outcomes and quality of life Br J Psychiatr 184 346 351
6. M Alvarez-Jiménez JF Gleeson SM Cotton D Wade K Crisp MB Yap PD McGorry 2008 Differential predictors of critical comments and emotional over-involvement in first-episode psychosis Psychol Med 15 1 10
7. Alvarez-Jiménez M, Parker AG, Hetrick SE, McGorry PD and Gleeson JF (2009a) Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull (in press). PMID:19900962
8. M Alvarez-Jiménez JF Gleeson S Cotton D Wade D Gee T Pearce K Crisp D Spiliotacopoulos B Newman PD McGorry 2009 Predictors of adherence to cognitive-behavioural therapy in first-episode psychosis Can J Psychiatry 54 10 710 718 19835678
9. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Washington DC
10. S Andersson HE Barder T Hellvin H Lövdahl UF Malt 2008 Neuropsychological and electrophysiological indices of neurocognition in bipolar II disorder Bipolar Disord 10 888 899 19594504
11. AC Andreazza F Kapczinski M Kauer-Sant'Anna JC Walz DJ Bond CA Goncales LT Young LN Yatham 2009 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder Neuroscience 34 263 271
12. T Archer B Adolphsson E Karlsson 2008 Affective personality as cognitive-emotional presymptom profiles regulatory for self-reported health predispositions Neurotox Res 14 21 44 18790723
13. MK Aronson LO Wee LG Dalia D Masur A Blau W Frishman 1991 Dementia: age-dependent incidence, prevalence, and mortality in the old old Arch Intern Med 151 989 992 2025148
14. MJ Arranz D Collier M Sodhi D Ball G Roberts J Price P Sham R Kerwin 1995 Association between clozapine response and allelic variation in 5-HT2A receptor gene Lancet 346 281 282 7630250
15. MJ Arranz J Munro MJ Owen G Spurlock PC Sham J Zhao G Kirov DA Collier RW Kerwin 1998 Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine Mol Psychiatr 3 61 66 (Pubitemid 28045186)
16. L Arseneault M Cannon J Witton RM Murray 2004 Causal association between cannabis and psychosis: examination of the evidence Br J Psychiatr 184 110 117 (Pubitemid 38186851)
17. F Benazzi 2007 Bipolar disorder-focus on bipolar II disorder and mixed depression Lancet 369 935 945 17368155
18. S Bender M Weisbrod F Resch 2007 Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia J Neural Transm 114 1199 1215 17514428
19. Berg S (1996) Aging, behavior and terminal illness. In: Brirren JE, Schale KW (eds) Handbook of the psychology of aging, 34th edn. Academic Press, New York, pp 181-197
20. M Berk KT Hallam PD McGorry 2007 The potential utility of a staging model as a course specifier: a bipolar disorder perspective J Affect Disord 100 279 281 17433450
21. M Berk GS Malhi KT Hallam CS Gama S Dodd AC Andreazza BN Frey F Kapczinski 2009 Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives J Affect Disorder 114 1 13
22. G Bersani V Orlandi GD Kotzalidis P Pancheri 2002 Cannabis and schizophrenia: impact on onset, course, psychopathology, and outcomes Eur Arch Psychiatr Clin Neurosci 252 86 92
23. M Bertelsen P Jeppesen L Petersen A Thorup J Ohlenschlaeger P le Quach TO Christensen G Krarup P Jorgensen M Nordentoft 2008 Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial Arch Gen Psychiatry 65 762 771 18606949
24. M Bertelsen P Jeppesen L Petersen A Thorup J Øhlenschlaeger P Le Quach T Østergaard Christensen G Krarup P Jørgensen M Nordentoft 2009 Course of illness in a sample of 265 patients with first-episode psychosis-five-year follow-up of the Danish OPUS trial Schizophr Res 107 173 178 18945593
25. S Bhattacharyya JA Crippa R Martin-Santos T Winton-Brown P Fusar-Poli 2009 Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology Curr Pharm Des 15 2603 2614 19689331
26. M Birchwood P Todd C Jackson 1998 Early intervention in psychosis. The critical period hypothesis Brit J Psychiatr [Suppl.] 172 53 59 (Pubitemid 28258899)
27. S Bonaccorso AH Lin R Verkerk F Van Hunsel I Libbrecht S Scharpe L DeClerck M Biondi A Janca M Maes 1998 Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers J Affect Disord 48 75 82 9495605
28. CM Bonnin A Martinez-Aran C Torrent I Pacchiarotti AR Rosa C Franco A Murru J Sanchez-Moreno E Vieta 2010 Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term follow-up study J Affect Disord 121 156 160 19505727
29. M Bonn-Miller M Zvolensky A Bernstein 2007 Marijuana use motives: concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers Addict Behav 32 49 62 16647822
30. SJ Borgwardt A Riecher-Rössler P Dazzan X Chitnis J Aston M Drewe U Gschwandtner S Haller M Pflüger E Rechsteiner M D'Souza RD Stieglitz EW Radü PK McGuire 2007 Regional gray matter volume abnormalities in the at risk mental state Biol Psychiatr 61 1148 1156
31. SJ Borgwardt PK McGuire J Aston U Gschwandtner M Pflüger RD Stieglitz EW Radü A Riecher-Rössler 2008 Reductions in frontal lobe and parietal volume associated with the onset of psychosis Schizophr Res 106 108 114 18789654
32. P Bosanac GC Patton DJ Castle 2010 Early intervention in psychotic disorders: faith before facts? Psychol Med 40 353 358 20120515
33. Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS, for the EUFEST Study Group (2010) Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry 71:58-65
34. H Boter J Peuskens J Libiger WW Fleischhacker M Davidson S Galderisi RS Kahn EUFEST study group 2009 Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST) Schizophr Res 115 97 103 19819114
35. D Braida V Liminta L Malabarba A Zani M Sala 2007 5-HT(1A) receptors are involved in the anxiolytic effect of delta(9)-tetrahydrocannabinol and AM404, the anandamide transport inhibitor, in Sprague-Dawley rats Eur J Pharmacol 555 156 163 17116299
36. WJ Brewer SM Francey SJ Wood HJ Jackson C Pantelis LJ Phillips AR Yung VA Anderson McGorry 2005 Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis Am J Psychiatr 162 71 78 15625204
37. Broome MR, Matthiasson P, Fusar-Poli P, Woolley JB, Johns LC, Tabraham P, Bramon E, Valmaggia L, Williams SC, Brammer MJ, Chitnis X, McGuire PK (2010) Neural correlates of movement generation in the 'at-risk mental state'. Acta Psychiatr Scand. PMID:20064129
38. PW Burnet PJ Harrison 1995 Genetic variation of the 5-HT2A receptor and response to clozapine Lancet 346 909 7564705
39. ES Burstein J Ma S Wong Y Gao E Pham AE Knapp NR Nash R Olsson RE Davis U Hacksell DM Weiner MR Brann 2005 Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist J Pharmacol Exp Ther 315 1278 1287 16135699
40. TD Cannon K Cadenhead B Cornblatt SW Woods J Addington E Walker LJ Seidman D Perkins M Tsuang T McGlashan R Heinssen 2008 Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America Arch Gen Psychiat 65 28 37 18180426
41. L Capuron S Su AH Miller JD Bremner J Goldberg GJ Vogt C Maisano L Jones NV Murrah V Vaccarino 2009 Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry 64 896 900
42. S Carbone S Harrigan PD McGorry C Curry K Elkins 1999 Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach Acta Psychiatr Scand 100 96 104 10480195
43. GA Carlson RL Findling RM Post B Birmaher HP Blumberg C Correll MP DelBello M Fristad J Frazier C Hammen SP Hinshaw R Kowatch E Leibenluft SE Meyer MN Pavuluri KD Wagner M Tohen 2009 AACAP 2006 Research Forum-Advancing research in early-onset bipolar disorder: barriers and suggestions J Child Adolesc Psychopharmacol 19 3 12 19232018
44. WT Carpenter JR Bustillo GK Thaker J van Os RF Krueger MJ Green 2009 The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11 Psychol Med 39 2025 2042 19796428
45. G Cassens L Wolfe M Zola 1990 Neuropsychology of depression J Neuropsychiatry Clin Neurosci 2 202 213 2136077
46. RC Chan Y Wang EF Cheung J Cui Y Deng Y Yuan Z Ma X Yu Z Li Q Gong 2009 Sustained attention deficit along the psychosis proneness continuum: a study on the Sustained Attention to Response Task (SART) Cogn Behav Neurol 22 180 185 19741328
47. Chase TN (2010) Apathy in neuropsychiatric disease: diagnosis, pathophysiology and treatment. Neurotoxicity Res
48. SF Chen YC Shen CH Chen 2009 HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients Psychopharmacology 205 285 292 19387614
49. SF Chen YC Shen CH Chen 2009 Effects of the DRD3 ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors Prog Neuropsychopharmacol Biol Psychiatr 33 470 474
50. DE Clarke R Reekum M Simard DL Streiner M Freedman D Conn 2007 Apathy in dementia: an examination of the psychometric properties of the apathy evaluation scale J Neuropsychiatry Clin Neurosci 19 57 64 17308228 (Pubitemid 46294446)
51. M Clerici B Arosio E Mundo E Cattaneo S Pozzoli B Dell'osso C Vergani D Trabattoni AC Altamura 2009 Cytokine polymorphisms in the pathophysiology of mood disorders CNS Spectr 14 419 425 19890236
52. F Colom E Vieta 2009 The road to DSM-V: bipolar disorder episode and course specifiers Psychopathology 42 209 218 19451753
53. F Colom E Vieta J Sánchez-Moreno R Palomino-Otiniano M Reinares JM Goikolea A Benabarre A Martínez-Arán 2009 Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial Br J Psychiatry 194 260 265 19252157
54. MT Compton AC Furman NJ Kaslow 2004 Lower negative symptom scores among cannabis-dependent patients with schizophrenia spectrum disorders: preliminary evidence from an African-American first-episode sample Schizophr Res 71 61 64 15374573
55. MT Compton ME Kelley CE Ramsay M Pringle SM Goulding ML Esterberg T Stewart EF Walker 2009 Association of pre-onset cannabis, alcohol, and tobacco use with at onset of prodromal and age at onset of psychosis in first-episode patients Am J Psychiatr 166 1251 1257 19797432
56. P Conus M Berk PD McGorry 2006 Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? Aust NZ J Psychiatr 40 199 207
57. B Crespo-Facorro R Perez-Iglesias M Ramirez-Bonilla O Martinez-Garcia J Llorca JL Vazquez-Barquero 2006 A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis J Clin Psychiatr 67 1511 1521
58. Crespo-Facorro B, Arranz MJ, Mata I, Vazquez-Bourgon J, Perez-Iglesias R, Medina-Gonzalez L, Pelayo-Teran JM, Carrasco-Marin E, Vazquez-Barquero JL (2010, in press) 5-HT2A polymorphisms and negative symptoms response to antipsychotic treatment: evidence of association in first episode psychosis patients. Neurotoxicity Res
59. JA Crippa AW Zuardi R Martin-Santos S Bhattacharyya Z Atakan P McGuire P Fusar-Poli 2009 Cannabis and anxiety: a critical review of the evidence Hum Psychopharmacol 24 515 523 19693792
60. NA Crossley A Mechelli P Fusar-Poli MR Broome P Matthiasson LC Johns E Bramon L Valmaggia SCR Williams PK McGuire 2009 Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and first-episode psychosis Hum Brain Mapp 30 4129 4137 19530219
61. M Csikszentmihalyi 2000 Happiness, flow, and economic equality Am Psychol 55 1163 1164 11080848
62. J Cullberg S Levander R Holmqvist M Mattsson IM Weiselgren 2002 One-year outcome in first episode psychosis patients in the Swedish Parachute project Acta Psychiatr Scand 106 276 285 12225494
63. AB Cunha BN Frey AC Andreazza JD Goi AR Rosa CA Goncales A Santin F Kapczinski 2006 Serum brain derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes Neurosci Lett 398 215 219 16480819
64. AB Cunha AC Andreazza FA Gomes BN Frey LE da Silveira CA Goncales F Kapczinski 2008 Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder Eur Arch Psychiatr Clin Neurosci 258 300 304
65. KR Daffner MM Mesulam LG Cohen 1999 Mechanisms underlying diminished novelty-seeking behavior in patients with probable Alzheimer's disease Neurocase 12 58 66
66. P Dannon K Lowengrub R Amiaz l Grunhaus M Kotler 2004 Comorbid cannabis use and panic disorder: short term and long term follow-up study Hum Psychopharmacol 19 97 101 14994319
67. IR Dinu S Popa M Bîcu E Moţa M Moţa 2009 The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects Rom J Intern Med 47 9 18 19886064
68. RL Drijgers P Aalten A Winogrodzzka FR Verhey AF Leentjens 2009 Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review Dement Geriatr Cogn Disorder 28 13 22
69. A Duffy M Alda T Hajek SB Sherry P Grof 2010 Early stages in the development of bipolar disorder J Affect Disord 121 127 135 19541368
70. PR Dunbar J Hill TJ Neale GW Mellsop 1992 Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia Psychol Med 22 1051 1057 1488478
71. JM Eagles JAG Beattie DB Restall F Rawlinson S Hagen GW Ashcroft 1990 Relation between cognitive impairment and early death in the elderly Br Mad J 300 239 241
72. AD Eastvold RK Heaton KS Cadenhead 2007 Neurocognitive deficits in the (putative) prodrome and first episode of psychosis Schizophr Res 93 266 277 17467955
73. J Edvardsen S Torgersen E Roysamb S Lygren I Skre S Onstad PA Oien 2008 Heritability of bipolar spectrum disorders: unity or heritability? J Affect Disord 106 229 240 17692389
74. J Egeland A Lund NI Landrö BR Rund K Sundet A Asbjørnsen N Mjellem A Roness KI Stordal 2005 Cortisol level predicts executive and memory function in depression, symptom level predicts psychmotor speed Acta Psychiatr Scand 112 434 441 16279872
75. SM Eggan DA Lewis 2007 Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis Cereb Cort 17 175 191
76. A Faerden R Nesvåg EA Barrett I Agartz A Finset S Friis JI Rossberg I Melle 2008 Assessing apathy: the use of the Apathy Evaluation Scale in first episode psychosis Eur Psychiatr 23 33 39
77. Frommann I, Pukrop R, Brinkmeyer J, Bechdolf A, Ruhrmann S, Berning J, Decker P, Möller HJ, Wölwer W, Gaebel W, Klosterkötter J, Maier W, Wagner M (2010) Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early-and additional memory dysfunction in the late-prodromal state
78. MA Frye G Helleman SL McElroy LL Altshuler DO Black PE Keck Jr WA Nolen R Kupka GS Leverich H Grunze J Mintz RM Post T Suppes 2009 Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression Am J Psychiatr 166 164 172 19015231
79. Fusar-Poli P, Byrne M, Valmaggia L, Day F, Tabraham P, Johns L, McGuire P, on behalf of the OASIS Team (2009b) Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. J Psychiatr Res. PMID:19836755
80. P Fusar-Poli P Allen S Bhattacharyya JA Crippa A Mechelli S Borgwardt R Martin-Santos MI Seal C O'Carrol Z Atakan AW Zuardi P McGuire 2009 Modulation of effective connectivity during emotional processing by Δ9- tetrahydrocannabinol and cannabinol Int J Neuropsychopharmacol 24 1 12
81. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire PK (2009a) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatr. PMID:19949389
82. S Galderisi M Davidson RS Kahn A Mucci H Boter MD Gheorghe JK Rybakowski J Libiger S Dollfus JJ López-Ibor J Peuskens LG Hranov WW Fleischhacker EUFEST group 2009 Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study Schizophr Res 115 104 114 19822407
83. Gardner H, Csikszentmihalyi M, Damon W (2002) Good work: when excellence and ethics meet. Basic Books, New York
84. D Gilder P Lau M Dixon L Corey E Phillips C Ehlers 2006 Comorbidity of select anxiety, affective, and psychotic disorders with cannabis dependence in southwest california indians J Addict Dis 25 67 79 17088227
85. M Gitlin K Nuechterlein KL Subotnik KL J Ventura J Mintz DL Fogelson G Bartzokis M Aravagiri 2001 Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia Am J Psychiatr 158 1835 1842 11691689
86. SM Goulding E McClure-Tone MT Compton 2009 Associations between multiple dimensions of schizotypy and sociodemographic variables in a nonpsychiatric sample of young adults J Nerv Ment Dis 197 786 789 19829209
87. B Green R Young D Kavanagh 2005 Cannabis use and misuse prevalence among people with psychosis Br J Psychiatr 187 306 313
88. H Häfner 2000 Onset and early course as determinants of the further course of schizophrenia Acta Psychiatr Scand 102 Suppl. 407 s44 s48
89. H Häfner K Maurer W Löffler A Riecher-Rössler 1993 The influence of age and sex on the onset and early course of schizophrenia Br J Psychiat 162 80 86
90. H Häfner K Maurer W Löffler W an der Heiden M Hambrecht F Schultze-Lutter 2003 Modelling the early course of schizophrenia Schizophr Bull 29 325 340 14552507
91. M Hambrecht H Häfner 2000 Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective Austr NZ J Psychiatr 34 468 475
92. SM Harrigan PD McGorry H Krstev 2003 Does treatment delay in first-episode psychosis really matter? Psychol Med 33 97 110 12537041
93. I Harrison EM Joyce MH Mutsatsa SB Hutton V Huddy M Kapasi TR Barnes 2008 Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study Psychol Med 38 79 88 17532864
94. LA Hazelwood E Sanders-Bush 2004 His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation Mol Pharmacol 66 1293 1300 15496511
95. TB Herbert S Cohen 1993 Stress and immunity in humans Psychosom Med 55 364 379 8416086
96. SE Hetrick AG Parker IB Hickie R Purcell AR Yung PD McGorry 2008 Early identification and intervention in depressive disorders: towards a clinical staging model Psychother Psychosom 77 263 270 18560251
97. SE Hetrick M Simmons S Merry 2008 SSRIs and depression in children and adolescents: the imperative for shared decision-making Australia Psychiatr 16 354 358
98. S Hollinghurst D Kessler TJ Peters D Gunnell 2005 Opportunity cost of antidepressant prescribing in England: analysis of routine data BMJ 330 999 1000 15778232
99. OD Howes AJ Montgomery MC Asselin RM Murray I Valli P Tabraham E Bramon-Bosch L Valmaggia L Johns M Broome PK McGuire PM Grasby 2009 Elevated striatal dopamine function linked to prodromal signs of schizophrenia Arch Gen Psychiatr 66 13 20 19124684
100. CL Hsieh AM Bowcock LA Farrer JM Hebert KN Huang LL Cavalli-Sforza D Julius U Francke 1990 The serotonin subtype 2 locus HTR2 is on human chromosome 13 near genes for esterase D and retinoblastoma-1 and on mouse chromosome 14 Somat Cell Mol Genet 16 567 574 1980030
101. JG Hunsberger DR Austin G Chen HK Manji 2009 Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity Brain Res 1293 76 84 19595676
102. TR Insel 2009 Translating scientific opportunity into public health impact: a strategic plan for research on mental illness Arch Gen Psychiat 66 128 133 19188534
103. M Irwin 1999 Immune correlates of depression Adv Exp Med Biol 461 1 24 10442164
104. G Isacsson G Boethius S Henriksson JK Jones U Bergman 1999 Selective serotonin reuptake inhibitors have broadened the utilization of antidepressant treatment in accordance with recommendations: findings from a Swedish database Affect Disord 53 15 22
105. V Isella P Melzi M Grimaldi S Iurlaro R Piolti C Ferrarese L Frattola I Appollonio 2002 Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease Mov Disord 17 366 371 11921125
106. V Isella S Iurlaro R Piolti C Ferrarese L Frattola I Appollonio 2003 Physical anhedonia in Parkinson's disease J Neurol Neurosurg Psychiatr 74 1308 1311 12933942
107. B Johansson SH Zarit 1997 Early cognitive markers of the incidence of dementia and mortality: a longitudinal population-based study of the oldest old Int J Ger Psychiatr 12 53 59
108. RS Kahn WW Fleischhacker H Boter M Davidson Y Vergouwe IP Keet MD Gheorghe JK Rybakowski S Galderisi J Libiger M Hummer S Dollfus JJ López-Ibor LG Hranov W Gaebel J Peuskens N Lindefors A Riecher-Rössler DE Grobbee the EUFEST study group 2008 Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet 371 1085 1097 18374841
109. F Kapczinski BN Frey AC Andreazza M Kauer-Sant'Anna AB Cunha RM Post 2008 Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes Rev Bras Psiquiatr 30 243 245 18833425
110. F Kapczinski E Vieta AC Andreazza BN Frey FA Gomes J Tramontina M Kauer-Sant'anna R Grassi-Oliveira RM Post 2008 Allostatic load in bipolar disorder: implications for pathophysiology and treatment Neurosci Biobehav Rev 32 675 692 18199480
111. F Kapczinski VV Dias M Kauer-Sant'Anna BN Frey R Grassi-Oliveira F Colom M Berk 2009 Clinical implications of a staging model for bipolar disorders Expert Rev Neurother 9 957 966 19589046
112. S Kasper MN Lerman RD McQuade A Saha WH Carson M Ali D Archibald G Ingenito R Marcus T Pigott 2003 Efficacy and safety of aripipazole vs. haloperidol for long-term maintainence treatment following acute relapse of schizophrenia Int J Neuropsychopharmacol 6 325 337 14609439
113. JP Kelly AS Wrynn BE Leonard 1997 The olfactory bulbectomized rat as a model of depression: an update Pharmacol Ther 74 299 316 9352586
114. MS Keshaven A Amirsadri 2007 Early intervention in schizophrenia: current and future perspectives Curr Psychiat Rep 9 325 328
115. LV Kessing MG Hansen PK Andersen Angst 2004 The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders-a life-long perspective Acta Psychiatr Scand 109 339 344 15049770
116. TA Ketter JP Houston DH Adams RC Risser Meyers Al DK Williamson M Tohen 2006 Differential efficacy of olanzepine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes J Clin Psychiatr 67 95 101
117. Killackey E, McGorry PD (2009) Interventions in the early stages of psychosis. Psychiatr Ann (in press). PMID:18836852
118. B Kim EY Choi CY Kim K Song YH Joo 2008 Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting Hum Psychopharmacol 23 61 67 17924589
119. DN Kiosses S Klimstra C Murphy GS Alexopoulos 2001 Executive dysfunction and disability in elderly patients with major depression Am J Geriatr Psychiatr 9 269 274
120. L Kirsch-Darrow HH Fernandez M Marsiske MS Okun D Bowers 2006 Dissociating apathy and depression in Parkinson's disease Neurology 67 33 38 16832074
121. J Klosterkötter M Hellmich EM Steinmeyer F Schultze-Lutter 2001 Diagnosing schizophrenia in the initial prodromal phase Arch Gen Psychiatr 58 158 164 11177117
122. G Kuzis L Sabe C Tiberti F Dorrego SE Starkstein 1999 Neuropsychological correlates of apathy and depression in patients with dementia Neurology 52 1403 1407 10227625
123. HY Lane YC Chang CC Chiu ML Chen MH Hsieh WH Chang 2002 Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene Am J Psychiatr 159 1593 1595 12202283
124. L Larraga P Saz ME Dewey G Marcos A Lobo ZARADEMP Workgroup 2006 Validation of the Spanish version of the EURO-D scale: an instrument for detecting depression in older people Int J Geriatr Psychiatry 21 1199 1205 17006871
125. TK Larsen TH McGlashan JO Johannessen S Friis C Guldberg U Haahr M Horneland I Melle LC Moe S Opjordsmoen E Simonsen P Vaglum 2001 Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment Am J Psychiatr 158 1917 1919 11691702
126. M LeBlanc C Mérette J Savard H Ivers L Baillargeon CM Morin 2009 Incidence and risk factors of insomnia in a population-based sample Sleep 32 1027 1037 19725254
127. L Lechowski M Benoit P Chassagne I Vedel D Tortrat L Teillet B Vellas 2009 Persistent apathy in Alzheimer's disease as an independent factor of rapid functional decline: the REAL longitudinal cohort study Int J Geriatr Psychiatr 24 341 346
128. AFG Leentjens K Dujardin L Marsh P Martinez-Martin IH Richard SE Starkstein D Weintraub C Sampaio W Poewe O Rascol GT Stebbins CG Goetz 2008 Apathy and Anhedonia Rating Scales in Parkinson's disease: critique and recommendations Mov Disord 23 1004 2014
129. AFG Leentjens J Koester B Fruh DT Shepard P Barone JJ Houben 2009 The effect of pramipexole on mood and motivation symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies Clin Ther 61 886 895
130. MR Lemke HM Brecht J Koester PH Kraus H Reichmann 2005 Anhedonia, depression, and motor functioning in Parkinson's diseaseduring treatment with pramipexole J Neuropsychiatry Clin Neurosci 17 214 220 15939976
131. MR Lemke HM Brecht PH Kraus H Reichmann 2006 Effects of the dopamine agonist pramipexole on depression, anhedonis and motor functioning in Parkinson's disease J Neurol Sci 248 266 270 16814808
132. EJ Lenze MC Munin MA Dew RS Marin MA Butters ER Skidmore EM Whyte A Begley CF Reynolds 2009 Apathy after hip fracture: a potential target for intervention to improve functional outcomes J Neuropsychiatry Clin Neurosci 21 271 278 19776306
133. E Levander MA Frye S McElroy T Suppes H Grunze WA Nolen R Kupka PE Keck Jr GS Leverich LL Altshuler S Hwang J Mintz RM Post 2007 Alcoholism and anxiety in bipolar illness: differential lifetime anxiety comorbidity in bipolar I women with and without alcoholism J Affect Disord 101 211 217 17254638
134. GS Leverich RM Post PE Keck Jr LL Altshuler MA Frye RW Kupka WA Nolen T Suppes SL McElroy H Grunze K Denicoff MK Moravec D Luckenbaugh 2007 The poor prognosis of childhood-onset bipolar disorder J Pediatr 150 485 490 17452221
135. CH Lin SJ Tsai YW Yu HL Song PC Tu CB Sim CP Hsu KH Yang CJ Hong 1999 No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population NeuroReport 10 57 60 10094133
136. DH Linszen PM Dingemans ME Lenior 1994 Cannabis use and the course of recent-onset schizophrenic disorders Arch Gen Psychiatr 51 273 279 8161287
137. A Little 2009 Treatment-resistant depression Am Fam Physician 80 167 172 19621857
138. Lobo A, Lopez-Anton R, De-La-Camara C, Quintanilla MA, Campayo A, Santabarbara J, Martin A, Saz P, Marcos G, the ZARADEMP Workgroup (2010) Staging of cognitive impairment, incidence of dementia and mortality risk: a simple method based on the Mini Mental Status Examination. Neurotoxicity Res (in press)
139. A Lobo P Saz G Marcos, et al. 2005 The ZARADEMP-project on the incidence, prevalence and risk factors of dementia (and depression) in the elderly community: II. Methods and first results Eur J Psychiatr 19 40 54
140. A Lobo P Saz G Marcos JL Dia C De-la-Camara T Ventura JA Montañes A Lobo-Escolar S Aznar ZARADEMP Workgroup 2007 Prevalence of dementia in a southern European population in two different time periods: the ZARADEMP Project Acta Psychiatr Scand 116 299 307 17803760
141. A Lobo-Escolar JF Roy P Saz C De-la-Cámara G Marcos A Lobo ZARADEMP Workgroup 2008 Association of hypertension with depression in community-dwelling elderly persons: results from the ZARADEMP Project Psychother Psychosom 77 323 325 18701829
142. A Lobo-Escolar P Saz G Marcos MA Quintanilla A Campayo A Lobo ZARADEMP Workgroup 2008 Somatic and psychiatric comorbidity in the general elderly population: results from the ZARADEMP Project J Psychosom Res 65 347 355 18805244
143. U Lueken U Seidl L Völker E Schweiger A Kruse J Schröder 2007 Development of a short version of the Apathy Evaluation Scale specifically adapted for dementia nursing home residents Am J Geriatr Psychiatr 15 376 378
144. S Luzi PD Morrison J Powell M di Forti RM Murray 2008 What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox Res 14 105 112 19073418
145. GS Mahli B Ivanovski V Szekeres A Olley 2004 Bipolar disorder: it's all in the mind? The neurological profile of a biological disorder Can J Psychiatr 49 813 819
146. AK Malhotra D Goldman N Ozaki A Breier R Buchanan D Pickar 1996 Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine Am J Psychiatr 153 1092 1094 8678181
147. AK Malla RM Norman P Williamson 1993 Stability of positive and negative symptoms in schizophrenia Can J Psychiatr 38 617 621
148. LB Marangell CR Johnson B Kertz HA Zboyan JM Martinez 2002 Olanzapine in
149. RS Marin 1990 Differential diagnosis and classification of apathy Am J Psychiatr 147 22 30 2403472
150. RS Marin 1991 Apathy: a neuropsychiatric syndrome J Neuropsychiatry Clin Neurosci 3 243 254 1821241
151. Marin RS (1996) Apathy and related disorders of diminished motivation. In: Dickstein LJ, Riba MB, Oldham JM (eds) Review of psychiatry, vol 15. American Psychiatric Press, Washington DC, pp 205-242
152. RS Marin PA Wilkosz 2005 Disorders of diminished motivation J Head Trauma Rehabil 20 377 388 16030444
153. RS Marin S Firincigullari RC Biedrzycki 1991 Reliability and validity of the Apathy Evaluation Scale Psychiatr Res 38 143 162
154. RS Marin RC Biedrzycki S Firincigullari 1993 The sources of convergence between measures of apathy and depression J Affect Disord 28 117 124 8354767
155. RS Marin MA Butters BH Mulsant BG Pollock CF Reynolds 2003 Apathy and executive function in depressed elderly J Geriatr Psychiatr Neurol 16 112 118
156. L Marsh WM McDonald J Cummings B Ravina NINDS/NIMH Work Group on Depression, Parkinson's Disease 2006 Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group Mov Disord 21 148 158 16211591
157. M Marshall S Lewis A Lockwood, et al. 2005 Association between duration of untreated psychosis and in cohorts of first-episode outcome patients: a systematic review Arch Gen Psychiat 62 975 983 16143729
158. A Martinez-Aran E Vieta M Reinares F Colom C Torrent J Sánchez-Moreno A Benabarre JM Goikolea M Comes M Salamero 2004 Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder Am J Psychiatr 161 262 270 14754775
159. M Masellis V Basile HY Meltzer JA Lieberman S Sevy FM Macciardi P Cola A Howard F Badri MM Nothen W Kalow JL Kennedy 1998 Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenic patients Neuropsychopharmacology 19 123 132 9629566
160. O Mason M Startup S Halpin, et al. 2004 Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states' Schizophr Res 7 227 237
161. RJ Mathew WH Wilson NY Chiu TG Turkington TR Degrado RE Coleman 1999 Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration Acta Psychiatr Scand 100 67 75 10442442
162. RJ Mathew WH Wilson TG Turkington TC Hawk RE Coleman TR DeGrado J Provenzale 2002 Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography Psychiatry Res 116 173 185 12477601
163. TH McGlashan 1998 Early detection and intervention of schizophrenia: rationale and research Br J Psychiat 172 3 6
164. PD McGorry 2007 Issues for DSM-V: clinical staging, a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry Am J Psychiat 164 859 860 17541042
165. McGorry PD (2010) Staging in neuropsychiatry: a heuristic model for understanding, prevention and treatment. Neurotoxicity Res (in press)
166. PD McGorry AR Yung 2003 Early intervention in psychosis: an overdue reform Aust NZ J Psychiat 37 393 398
167. PD McGorry J Edwards C Mihalopoulos SM Harrigan HJ Jackson 1996 EPPIC: an evolving system of early detection and optimal management Schizophr Bull 22 305 326 8782288
168. PD McGorry AR Yung L Phillips 2001 Ethics and early intervention in psychosis: keeping up the pace and staying in step Schizophr Res 51 17 29 11479062
169. PD McGorry IB Hickie AR Yung C Pantelis HJ Jackson 2006 Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions Aust NZ J Psychiat 40 616 622
170. PD McGorry R Purcell IB Hickie AF Jorm 2007 Investing in youth mental health is a best buy Med J Austral 187 Suppl. 7 s5
171. PD McGorry E Killackey AR Yung 2008 Early intervention in psychosis: concepts, evidence and future directions World Psychiat 7 148 156
172. PD McGorry AR Yung A Bechdorf P Amminger 2008 Back to the future: predicting and reshaping the course of psychotic disorder Arch Gen Psychiatr 65 25 27 18180425
173. McGorry PD, Johannessen JO, Lewis S, Birchwood M, Malla A, Nordentoft M, Addington A, Yung A (2009a) Early intervention in psychosis: keeping faith with evidence-based health care. Psychol Med. PMID:19886337
174. PD McGorry B Nelson P Amminger A Bechdolf SM Francey G Berger A Riecher-Rössler J KlosterKötter S Ruhrmann F Schultze-Lutter M Nordentoft I Hickie P MsGuire M Berk YH Chen MS keshaven AR Yung 2009 Intervention in individuals at ultra high risk for psychosis: a review and future directions J Clin Psychiat 70 1206 1212
175. McGuire PK (2010) Brain imaging in early stages of psychosis. In: Palomo T, Beninger RJ, Kostrzewa RM, Archer T (eds) Staging neuropsychiatric disorders: implications for etiopathogenesis and treatment. F.P. Graham Publishing, Mountain Home USA
176. I Melle TK Larsen U Haahr S Friis JO Johannessen S Opjordsmoen E Simonsen BR Ruud P Vaglum T McGlashan 2004 Reducing the duration of untreated first-episode psychosis: effects on clinical presentation Arch Gen Psychiat 61 143 150 14757590 (Pubitemid 38146548)
177. I Melle TK Larsen S Friis P Vaglum JO Johannessen E Simonsen U Haahr S Opjordsmoen BR Ruud JL Rossberg I Joa W hegelstad H Langeveld J Evensen T McGlashan 2009 Early detection of first psychosis: TIPS sample five year outcomes Schizophr Bull 35 Suppl. 1 s330
178. J Mendlewicz 2009 Disruption of the circadian timing systems: molecular mechanisms in mood disorders CNS Drugs 23 Suppl 2 15 26 19708722
179. KR Merikangas HS Akiskal J Angst 2007 Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication Arch Gen Psychiatr 64 543 552 17485606
180. U Meyer J Feldon 2009 Neural basis of psychosis-related behaviour in the infection model of schizophrenia Behav Brain Res 204 322 334 19154759
181. AH Miller 2010 Depression and immunity: a role for T cells? Brain Behav Immun 24 1 8 19818725
182. TJ Miller TH McGlashan JL Rosen, et al. 2002 Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity Am J Psychiat 159 863 865 11986145
183. G Modinos A Mechelli J Ormel NA Groenewold A Aleman PK McGuire 2009 Schizotypy and brain structure: a voxel-based morphometry study Psychol Med 17 1 9
184. TH Moore S Zammit A Lingford-Hughes TR Barnes PB Jones M Burke G Lewis 2007 Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review Lancet 370 9584 319 328 17662880
185. TW Moorhead A Stanfield M Spencer J Hall A McIntosh DC Owens S Lawrie E Johnstone 2009 Progressive temporal lobe grey matter loss in adolescents with schizotypal traits and mild intellectual impairment Psychiatry Res 174 105 109 19833484
186. FA Moreira B Lutz 2008 The endocannabinoid system: emotion, learning and addiction Addict Biol 13 196 212 18422832
187. PD Morrison V Zois DA McKeown TD Lee DW Holt JF Powell S Kapur RM Murray 2009 The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning Psychol Med 39 1607 1616 19335936
188. G Moukas A Stathopoulou P Gourzis IN Beratis S Beratis 2010 Relationship of "prodromal" symptoms with severity and type of psychopathology in the active phase of schizophrenia Compr Psychiatry 51 1 7 19932819
189. N Müller MJ Schwarz 2007 The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression Mol Psychiatr 12 988 1000
190. N Müller MJ Schwarz 2007 The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view J Neurotransmiss 78 253-256 258-260 262 263
191. N Müller MJ Schwarz 2008 A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders Eur Arch Psychiatry Clin Neurosci 258 Suppl 2 97 106 18516521
192. N Müller MJ Schwarz 2008 COX-2 inhibition in schizophrenia and major depression Curr Pharm Des 14 1452 1465 18537668
193. N Müller MJ Schwarz S Dehning A Douhe A Cerovecki B Goldstein-Müller I Spellmann G Hetzel K Maino N Kleindienst HJ Möller V Arolt M Riedel 2006 The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Mol Psychiatry 11 680 684 16491133
194. N Müller AM Myint MJ Schwarz 2009 The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment Dialogues Clin Neurosci 11 319 332 19877499
195. Müller N, Myint AM, Schwarz MJ (2010) Inflammatory biomarkers and depression. Neurotoxicity Res (in press)
196. Murray KM (2010) Cannabis and psychosis. In: Palomo T, Beninger RJ, Kostrzewa RM, Archer T (eds) Staging neuropsychiatric disorders: implication for etiopathogenesis and treatment. Graham publ., Mountain View
197. CJ Murray AD Lopez 1997 Global mortality, disability, and the contributions of risk factors: global burden of disease study Lancet 349 1436 1442 9164317
198. RM Murray PD Morrison C Henquet M Di Forti 2007 Cannabis, the mind and society: the hash realities Nat Rev Neurosci 8 885 895 17925811
199. AM Myint HW Steinbusch L Goeghegan D Luchtman YK Kim BE Leonard 2007 Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bbulbectomised rat model of depression Neuroimmunomodulation 14 65 71 17713352
200. WE Narrow EA Kuhl DA Regier 2009 DSM-V perspectives on disentangling disability from clinical significance World Psychiatr 8 88 89
201. B Nelson MB Simmons AR Yung JA Buckby L O'Dwyer SM Francey S Leicester S Bapat PD McGorry 2008 Identifying the ultra-high risk (prodromal) population: evaluation of training workshops with mental health services Aust N Z J Psychiatr 42 236 243
202. FG Nery ES Monkul JP Hatch M Fonseca GB Zunta-Soares BN Frey CL Bowden JC Soares 2008 Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study Hum Psychopharmarcol 23 87 94
203. MM Nothen M Rietschel J Erdmann H Oberlander HJ Moller D Nober P Propping 1995 Genetic variation of the 5-HT2A receptor and response to clozapine Lancet 346 908 909 7564704
204. G Nowak M Siwek D Dudek A Zieba A Pilc 2003 Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study Pol J Pharmacol 55 1143 1147 14730113
205. S Nudmamud-Thanoi GP Reynolds 2004 The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders Neurosci Lett 372 173 177 15531111
206. PR Padala WJ Burke SC Bhatia F Petty 2007 Treatment of apathy with methylphenidate J Neuropsychiatry Clin Neurosci 19 81 83 17308232
207. T Palomo RJ Beninger RM Kostrzewa T Archer 2008 Focusing on symptoms rather than diagnosis in brain dysfunction: conscious and nonconscious expression in impulsiveness and decision-making Neurotoxicity Res 14 1 20
208. T Palomo RJ Beninger RM Kostrzewa T Archer 2008 Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths Neurotoxicity Res 14 79 96
209. DL Penn EJ Waldheter DO Perkins KT Mueser JA Lieberman 2005 Psychosocial treatment for first-episode psychosis: a research update Am J Psychiatr 162 2220 2232 16330584
210. DO Perkins H Gu K Boteva JA Lieberman 2005 Relationship between duration of untreated psychosis and in cohorts of first-episode outcome schizophrenia: a critical review and meta-analysis Am J Psychiat 162 1785 1804 16199825
211. MO Pflüger U Gschwander RD Stieglitz A Riecher-Rössler 2007 Neuropsychological deficits in individuals with an at risk mental state for psychosis-working memory as a potential trait marker Schizophr Res 97 14 24
212. GC Pluck RG Brown 2002 Apathy in Parkinson' disease J Neurol Neurosurg Psychiatr 73 636 642 12438462
213. RM Post 2008 Promising avenues of therapeutics for bipolar illness Dialogues Clin Neurosci 10 193 201 18689289
214. Post RM (2010) Mechanisms of illness progression in the recurrent affective disorders. Neurotoxicity Res (in press)
215. RM Post GS Leverich 2006 The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: the need for earlier and alternative modes of therapeutic intervention Dev Psychopathol 18 1181 1211 17064434
216. Pukrop R, Klosterkötter J (2010) Neurocognitive indicators of clinical high-risk states for psychosis: a critical review of the evidence. Neurotoxicity Res (in press)
217. R Pukrop S Ruhrmann F Schultze-Lutter A Bechdolf A Brockhaus-Dumke J Klosterkötter 2007 Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis Schizophr Res 92 116 125 17344028
218. S Quraishi S Frangou 2002 Neuropsychology of bipolar disorder: a review J Affect Disord 72 209 226 12450638
219. N Realini T Rubino D Parolaro 2009 Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids Pharmacol Res 60 132 138 19559364
220. DA Regier WE Narrow EA Kuhl DJ Kupfer 2009 The conceptual development of DSM-V Am J Psychiatr 166 645 650 19487400
221. Reid IC, Cameron IM (2010) The HEAT is on: demonizing antidepressant drugs in Scotland (in press)
222. M Reinares F Colom J Sánchez-Moreno C Torrent A Martínez-Arán M Gomes JM Goikolea A Benabarre M Salamero E Vieta 2008 Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial Bipolar Disord 10 511 519 18452447
223. Reinares M, Colom F, Rosa AR, Bonnin CM, Franco C, Solé B, Kapczinski F, Vieto E (2009) The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disorder. PMID:19853922
224. C Reist C Mazzanti R Vu K Fujimoto D Goldman 2004 Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5.HT2A candidate allelle: His452Tyr Mol Psychiatr 9 871 878
225. A Riecher-Rössler U Gschwandtner J Aston S Borgwardt M Drewe P Fuhr M Pflüger W Radü Ch Schindler RD Stieglitz 2007 The Basel early-detection-of-psychosis (FEPSY)-study-design and preliminary results Acta Psychiat Scand 115 114 125 17244175
226. A Riecher-Rössler U Gschwander SJ Borgwardt J Aston M Pflüger W Rössler 2006 Early detection and treatment of schizophrenia: how early? Acta Psychiatr Scand 113 73 80
227. A Riecher-Rössler MO Pflueger J Aston SJ Borgwardt WJ Brewer U Gschwandtner RD Stieglitz 2009 Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up Biol Psychiatry 66 1023 1030 19733837
228. Riemer S, Maes M, Christophe A, Rief W (2009) Lowered omega-3 PUFAs are related to major depression, but not to somatization syndrome. J Affect Disord. PMID:19720401
229. PH Robert S Clairet M Benoit J Koutaich C Bertogliati O Tible H Caci M Borg P Broker P Bedoucha 2002 The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment Int J Geriatr Psychiatr 17 1099 1105
230. PH Robert CU Onyike AF Leentjens K Dujardin P Aalten S Starkstein FR Verhey J Yessavage JP Clement D Drapier F Bayle M Benoit P Boyer PM Lorca F Thibaut S Gauthier G Grossberg B Vellas J Byrne 2009 Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders Eur Psychiatry 24 98 104 19201579
231. LJ Robinson IN Ferrier 2006 Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence Bipolar Disord 8 103 116 16542180
232. D Robinson MG Woerner JM Alvir S Geisler A Koreen B Sheitman M Chakos D Mayerhoff R Bilder R Goldman JA Lieberman 1999 Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder Arch Gen Psychiatr 56 241 247 10078501 (Pubitemid 29125132)
233. D Robinson MG Woerner HM Delman JM Kane 2005 Pharmacological treatments for first episode schizophrenia Schizophr Bull 31 705 722 16006592
234. J Rodda S Morgan Z Walker 2009 Are cholinesterase inhibitors effective in the management of the behavioural and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Int Psychogeriatr 21 813 824 19538824
235. AR Rosa C Franco A Martínez-Aran J Sánchez-Moreno M Reinares M Salamero C Arango JL Ayuso-Mateos F Kapczinski E Vieta 2008 Functional impairment in patients with remitted bipolar disorder Psychother Psychosom 77 390 392 18716425
236. AR Rosa M Reinares C Franco M Comes C Torrent J Sánchez-Moreno A Martínez-Arán M Salamero F Kapczinski E Vieta 2009 Clinical predictors of functional outcome of bipolar patients in remission Bipolar Disord 11 401 409 19500093
237. DR Royall 1999 Frontal systems impairment in major depression Semin Clin Neuropsychiatr 4 13 23
238. DR Royall RK Mahurin K Gray 1992 Bedside assessment of executive cognitive impairment: The Executive Interview (EXIT) J Am Geriatr Soc 40 1221 1226 1447438
239. S Ruhrmann F Schultz-Lutter J Klosterkotter 2003 Early detection and intervention in the initial prodromal phase of schizophrenia Pharmacopsychiat 36 Suppl. 3 S162 S167
240. S Ruhrmann J Paruch A Bechdolf R Pukrop M Wagner J Berning F Schultze-Lutter B Janssen W Gaebel HJ Möller W Maier J Klosterkötter 2008 Reduced subjective quality of life in persons at risk for psychosis Acta Psychiatr Scand 117 357 368 18241303
241. Rummel C, Hamann J, Kissling W, Leucht S (2003) New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev CD004410
242. BR Rund K Sundet A Asbjørnsen J Egeland NI Landrø A Lund A Roness KI Stordal K Hugdahl 2006 Neuropsychological test profiles in schizophrenia and non-psychotic depression Acta Psychiatr Scand 113 350 359 16638080
243. P Saz LJ Launer JL Día C De-La-Cámara G Marcos A Lobo 1999 Mortality and mental disorders in a Spanish elderly population Int J Geriatr Psychiatry 14 1031 1038 10607970
244. P Saz R López-Antón ME Dewey T Ventura A Martín G Marcos C De La Cámara MA Quintanilla B Quetglas M Bel A Barrera A Lobo 2009 Prevalence and implications of psychopathological non-cognitive symptoms in dementia Acta Psychiatr Scand 119 107 116 19053966
245. A Schrag P Barone RG Brown AF Leentjens WM McDonald S Starkstein D Weintraub W Poewe O Rascol C Sampaio GT Stebbins CG Goetz 2007 Depression rating scales in Parkinson's disease: critique and recommendations Mov Disord 22 1077 1092 17394234
246. J Scott E Paykel R Morriss R Bentall P Kinderman T Johnson R Abbott H Hayhurst 2006 Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomized controlled trial Br J Psychiatr 188 310 320
247. H Sheikholeslami C Kani K Kani H Ghafelebashi 2009 Repetition of suicide-related behavior: a study of the characteristics, psychopathology, suicidality and negative life events in Iran Int J Psychiatry Med 39 45 62 19650529
248. YC Shen SF Chen CH Chen CC Lin SJ Chen YJ Chen SU Luu 2009 Effects of DRD2/ANKKI gene variations and clinical factors on aripipazole efficacy in schizophrenic patients J Psychiatric Res 43 600 606
249. G Simic G Stanic M Mladinov N Jovanov-Milosevic I Kostovic PR Hof 2009 Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol 35 532 554 19682326
250. S Simpson E Barnes E Griffiths K Hood D Cohen N Craddock I Jones DJ Smith 2009 The Bipolar Interactive Psychoeducation (BIPED) study: trial design and protocol BMC Psychiatry 12 9 50
251. R Smieskova P Fusar-Poli P Allen K Bendfeldt RD Stieglitz EW Radu PK McGuire A Riecher-Rössler SJ Borgwardt 2009 The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?-a systematic review Curr Pharm Des 15 2535 2549 19689326
252. G Spurlock A Heils P Holmans J Williams UM D'Souza A Cardno KC Murphy L Jones PR Buckland P McGuffin KP Lesch MJ Owen 1998 A family based association study of T102C polymorphism in 5-HT2A and schizophrenia plus identification of new polymorphisms in the promotor Mol Psychiatr 3 42 49
253. SE Starkstein 2000 Apathy and withdrawal Int Psychogeriatr 12 Suppl 1 135 138
254. SE Starkstein AF Leentjens 2008 The nosological position of apathy in clinical practice J Neurol Neurosurg Psychiatr 79 1088 1092 18187477
255. SE Starkstein HS Mayberg TJ Preziosi P Andrezejewski R Leisguarda RG Robinson 1992 Reliability, validity, and clinical correlates of apathy in Parkinson's disease J Neuropsychiatry Clin Neurosci 4 134 139 1627973
256. SE Starkstein R Jorge R Mizrahi 2006 The prevalence, clinical correlates and treatment of apathy in Alzheimer's disease Eur J Psychiatr 20 96 106
257. J Stephenson 2000 Delay in treating schizophrenia may narrow therapeutic window of opportunity JAMA 283 2091 2092 10791488
258. Stewart T, Goulding SM, Esterberg ML, Pringle M, Compton MT (2010)
259. S Su AH Miller H Snieder JD Bremner J Ritchie C Maisano L Jones NV Murrah J Goldberg V Vaccarino 2009 Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study Psychosom Med 71 152 158 19073752
260. M Summers K Papadopoulou S Bruno L Cipol MA Ron 2006 Bipolar I and Bipolar II disorder: cognition and emotion processing Psychol Med 36 1799 1809 16938147
261. T Takahashi AR Yung M Yücel SJ Wood LJ Phillips IH Harding B Soulsby PD McGorry M Suzuki D Velakoulis C Pantelis 2008 Prevalence of large cavum septi pellucidi in ultra high-risk individuals and patients with psychotic disorders Schizophr Res 105 236 244 18693084
262. T Takahashi SJ Wood AR Yung LJ Phillips B Soulsby PD McGorry R Tanino SY Zhou M Suzuki D Velakoulis C Pantelis 2009 Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis Schizophr Res 111 94 102 19349150
263. E Taylor 2009 Managing bipolar disorders in children and adolescents Nat Rev Neurol 5 484 491 19668245
264. S Therman JM Suvisaari H Kalska MO Huttunen M Manninen TD Cannon 2009 Lack of association between neuropsychological performance and level of psychosis-proneness in an adolescent psychiatric sample J Nerv Ment Dis 197 669 674 19752646
265. C Torrent A Martínez-Arán C Daban J Sánchez-Moreno M Comes JM Goikolea M Salamero E Vieta 2006 Cognitive impairment in bipolar II disorder Br J Psychiatr 189 254 259
266. C Torrent A Martínez-Arán B Amann C Daban R Tabarés-Seisdedos A González-Pinto M Reinares A Benabarre M Salamero P McKenna E Vieta 2007 Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects Acta Psychiatr Scand 116 453 460 17997724
267. S Uzun O Kozumplik N Mimica V Folnegovic-Smalc 2005 Aripipazole: an overview of a novel antipsychotic Psychiatr Danub 17 67 75 16395846
268. V Vaccarino ML Brennan AH Miller JD Bremner JC Ritchie F Lindau E Veledar S Su L Jones F Jawed J Dai J Goldberg SL Hazen 2008 Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study Biol Psychiatry 64 476 483 18514165
269. V Vaccarino R Lampert JD Bremner F Lee S Su C Maisano NV Murrah L Jones F Jawed N Afzal A Ashraf J Goldberg 2008 Depressive symptoms and heart rate variability: evidence for a shared genetic substrate in a study of twins Psychosom Med 70 628 636 18606724
270. V Vaccarino J Votaw T Faber E Veledar NV Murrah LR Jones J Zhao S Su J Goldberg JP Raggi AA Quyyumi DS Sheps JD Bremner 2009 Major depression and coronary flow reserve detected by positron emission tomography Arch Intern Med 169 1668 1676 19822823
271. E Van Duijn EM Kingma RC van der Mast 2007 Psychopathology in verified Huntington's disease gene carriers J Neuropsychiatry Clin Neurosci 19 441 448 18070848
272. Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, Martinez-Aran A, Kaczinski F (2009) The clinical implications of cognitive impairment and allostatic load in bipolar disorder. J Clin Psychiatr (in press). PMID:19906078
273. Vieta E, Reinares M, Rosa AR (2010) Staging bipolar disorder. Neuroyoxicity Res (in press)
274. D Wade 2005 Cannabis use and schizophrenia Am J Psychiatr 162 401 402 15677616
275. ER Watkins 2009 Depressive rumination and co-morbidity: evidence for brooding as a transdiagnostic process J Ration Emot Cogn Behav Ther 27 160 175 19718267
276. PJ Weiden M Olfson 1995 Cost of relapse in schizophrenia Schizophr Bull 21 419 429 7481573
277. D Weintraub PJ Moberg JE Duda IR Katz MB Stren 2004 Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease J Am Geriatr Soc 52 784 789 15086662
278. D Wiersma FJ Nienhuis CJ Slooff R Giel 1998 Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort Schizophr Bull 24 75 85 9502547
279. MM Williams CM Roe JC Morris 2009 Stability of the Clinical Dementia Rating, 1979-2007 Arch Neurol 66 773 777 19506139
280. K Witt C Daniels J Herzog D Lorenz J Volkmann J Reiff M Mehdorn G Deuschl P Krack 2006 Differential effects of l-Dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease J Neuropsychiatry Clin Neurosci 18 397 401 16963590
281. H Witthaus C Kaufmann G Bohner S Özgurdal Y Gudlowski J Gallinat S Ruhrmann M Brune A Heinz R Klingebiel G Juckel 2009 Gray matter abnormalities in subjects at high-risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls Psychiatr Res 173 163 169
282. SJ Wood C Pantelis AR Yung D Velakoulis PD McGorry 2009 Brain changes during the onset of schizophrenia: implications for neurodevelopmental theories Med J Aust 190 4 Suppl S10 S13 19220166
283. LN Yathan F Kapczinski AC Andreazza TL Young RW Lam M Kauer-Sant'anna 2009 Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder Int J Neuropsychopharmacol 12 137 139
284. YW Yu SJ Tsai KH Yang CH Lin MC Chen CJ Hong 2001 Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine Neuropsychobiology 43 79 82 11174050
285. AR Yung LJ Phillips PD McGorry CA McFarlane S Francey S Harrigan GC Patton HJ Jackson 1998 Prediction of psychosis: a step towards indicated prevention of schizophrenia Br J Psychiat Suppl 172 14 20
286. AR Yung LJ Phillips HP Yuen PD McGorry 2004 Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features Schizophr Res 67 131 142 14984872
287. AR Yung B Nelson C Stanford NB Simmons EM Cosgrave E Killackey LJ Phillips A Bechdolf J Buckby PD McGorry 2008 Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up Schizophr Res 105 10 17 18765167
288. AR Yung B Nelson K Baker JA Buckby G Baksheev EM Cosgrave 2009 Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia Aust NZ J Psychiat 43 118 128
289. LB Zahodne S Young L Kirsch-Darrow A Nisenzon HH Fernandez MS Okun Bowers 2009 Examination of the Lille Apathy Rating Scale in Parkinson's disease Mov Disord 24 677 683 19133658
290. S Zammit TH Moore A Lingford-Hughes TR Barnes PB Jones M Burke G Lewis 2008 Effects of cannabis use on outcomes of psychotic disorders: systematic review Br J Psychiatr 193 357 363